LunGuard Medical Secures $100K
LunGuard Medical

Get the full LunGuard Medical company profile
Access contacts, investors, buying signals & more
LunGuard Medical has secured $100,000 in funding to advance its innovative technology for critical care medicine.
The company is developing a novel solution aimed at improving nutrition, treatment, and reducing nosocomial infections in Intensive Care Units (ICUs).
LunGuard's approach, termed "Personalized Physiological Medicine (PPM)," centers on a smart peristaltic enteral feeding tube designed as a multi-sensory platform.
This technology addresses critical challenges in the ICU, primarily by safely blocking Gastro Esophageal Reflux (GER) and mitigating nosocomial infections that can lead to Ventilator Associated Pneumonia (VAP).
VAP presents significant risks, causing life-threatening complications unrelated to a patient's initial hospitalization, necessitating complex medical interventions, deteriorating patient conditions, and prolonging their length of stay.
LunGuard's system is engineered to capture vital physiological data from various locations, including sealing mechanisms within the esophagus and Transpulmonary Pressure (TPP) from the respiratory airway.
It also monitors upper Gastrointestinal (GI) dysmotility through esophageal and stomach contractions.
Integrated pH/impedance sensors assess infection prevention effectiveness and facilitate accelerated feeding protocols, aiming for optimal patient recovery with minimal exposure to gastric aspiration infection.
A sophisticated AI algorithm processes this data in real-time to optimize infection prevention, feeding, and ventilation strategies.
This funding round marks a significant milestone for LunGuard Medical, providing essential capital to further its development efforts.
The $100,000 investment will be deployed to accelerate the refinement of its technology and support strategic growth initiatives as the company moves towards bringing its solution to critical care settings.
Looking ahead, LunGuard Medical aims to establish its technology as a foundational platform for personalized medicine in the ICU, ultimately enhancing patient outcomes and transforming critical care practices.
Unlock GTM Signals
Discover LunGuard Medical's tech stack and active buying intent signals.
View GTM SignalsTrusted by 200+ sales professionals
Unlock Investor Data
See who invested in LunGuard Medical and connect with key investment contacts.
Unlock InvestorsTrusted by 200+ sales professionals
Unlock Key Decision-Makers
Get direct access to the key decision-makers at LunGuard Medical.
Unlock Decision-MakersTrusted by 200+ sales professionals